267 related articles for article (PubMed ID: 28903456)
1. Tumor reductive therapies and antitumor immunity.
Guo H; Tsung K
Oncotarget; 2017 Aug; 8(33):55736-55749. PubMed ID: 28903456
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
Esposito A; Criscitiello C; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of melanoma: efficacy and mode of action.
Wieder T; Brenner E; Braumüller H; Röcken M
J Dtsch Dermatol Ges; 2016 Jan; 14(1):28-37. PubMed ID: 26713633
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
6. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
7. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
8. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
Ramsay AG
Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and lung cancer: current developments and novel targeted therapies.
Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
Dempke WC; Sellmann L; Fenchel K; Edvardsen K
Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
15. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model.
Son CH; Bae JH; Shin DY; Lee HR; Choi YJ; Jo WS; Ho Jung M; Kang CD; Yang K; Park YS
J Immunother; 2014 Jan; 37(1):1-7. PubMed ID: 24316550
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
18. Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications.
Derer A; Deloch L; Rubner Y; Fietkau R; Frey B; Gaipl US
Front Immunol; 2015; 6():505. PubMed ID: 26500646
[TBL] [Abstract][Full Text] [Related]
19. Combination of radiotherapy and immune checkpoint inhibitors.
Pilones KA; Vanpouille-Box C; Demaria S
Semin Radiat Oncol; 2015 Jan; 25(1):28-33. PubMed ID: 25481263
[TBL] [Abstract][Full Text] [Related]
20. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
